Gustafsson F, et al. - Experts sought to study the post-approval outcomes after treatment of advanced heart failure with HeartMate 3 (HM3), a fully magnetically levitated continuous flow left ventricular assist device (LVAD). This device was found to be highly reliable, with thrombosis-free outcomes, a low incidence of stroke, improved functional capacity and quality of life (QOL) after 6-months. There was no incidence of pump thrombosis in the enrolled primary implant patients. Major bleeding was 25%, major infection 35%, and any stroke type 5% for these patients. Findings suggested a significant improvement in the functional capacity along with improvement in QOL. At 6-months, freedom from unplanned rehospitalizations was 68 ± 2%.